Serum periostin in obstructive airways Disease

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1383-1391

  Fingleton, James ^a,b,c   Braithwaite, Irene ^a   Travers, Justin ^a,d   Bowles, Darren ^a,b   Strik, Rianne ^a   Siebers, Rob ^e   Holweg, Cecile ^f   Matthews, John ^f   Weatherall, Mark ^b,e   Beasley, Richard ^a,b,c  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^d Hutt Valley District Health Board   (New Zealand)

^e UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

^f GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BUDESONIDE; C REACTIVE PROTEIN; IMMUNOGLOBULIN E; NITRIC OXIDE; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; CORTICOSTEROID; POSTN PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; ASTHMA; ATOPY; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DYSPNEA; EOSINOPHIL COUNT; ETHNIC DIFFERENCE; FEMALE; FUNCTIONAL RESIDUAL CAPACITY; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTENSION; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; OBSTRUCTIVE AIRWAY DISEASE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RISK FACTOR; SEX DIFFERENCE; SMOKING; TREATMENT DURATION; WHEEZING; ABNORMAL RESPIRATORY SOUND; ADOLESCENT; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOLOGY; EOSINOPHIL; EXHALATION; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; NEW ZEALAND; QUESTIONNAIRE; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ASTHMA; BUDESONIDE; CELL ADHESION MOLECULES; CROSS-SECTIONAL STUDIES; EOSINOPHILS; EXHALATION; FEMALE; HUMANS; INFLAMMATION; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; NEW ZEALAND; NITRIC OXIDE; RESPIRATORY FUNCTION TESTS; RESPIRATORY SOUNDS; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84969790730     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01384-2015     Document Type: Article

References (32)

1. Taylor DR. Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol 2011; 128: 927-934.
2. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129: Suppl. 3, S9-S23.
3. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67: 199-208.
4. Malerba M, Ragnoli B, Radaeli A, et al. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest 2008; 134: 733-739.
5. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: A randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
6. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
7. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
8. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
9. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: An analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-811.
10. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
11. Hanania NA, Noonan M, Corren J, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70: 748-756.
12. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-654.
13. Nair P, Kraft M. Serum periostin as a marker of TH2-dependent eosinophilic airway inflammation. J Allergy Clin Immunol 2012; 130: 655-656.
14. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-15863.
15. Takayama G, Arima K, Kanaji T, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118: 98-104.
16. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107: 14170-14175.
17. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
18. Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol 2015, 136: 601-609.
19. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
20. American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
21. Juniper EF, Svensson K, Mork AC, et al. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-538.
22. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
23. Ferris BG. Recommended respiratory disease questionnaires for use with adults and children in epidemiological research: epidemiology standardization project. Am Rev Respir Dis 1978; 118: 7-53.
24. Dorn GW II. Periostin and myocardial repair, regeneration, and recovery. N Engl Med J 2007; 357: 1552-1554.
25. Khn B, del Monte F, Hajjar RJ, et al. Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 2007; 13: 962-969.
26. Sutherland TJ, Cowan JO, Young S, et al. The association between obesity and asthma: Interactions between systemic and airway inflammation. Am J Respir Crit Care Med 2008; 178: 469-475.
27. Telenga ED, Tideman SW, Kerstjens HA, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy 2012; 67: 1060-1068.
28. Pavord ID, Bafadhel M. Exhaled nitriic oxide and blood eosinophilia: Independent markers of preventable risk. J Allergy Clin Immunol 2013; 132: 828-829.
29. Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol 2013; 132: 821-827.
30. Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013; 132: 72-80.
31. Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FeNo and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70: 115-120.
32. Arron J, Izuhara K. Asthma biomarkers: What constitutes a 'gold standard'? Thorax 2015; 70: 105-107.